FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005746290> ?p ?o ?g. }

• W2005746290 endingPage "1602" @default.
• W2005746290 startingPage "1597" @default.
• W2005746290 abstract "Transfusional iron overload is a potentially fatal complication of the treatment of thalassaemia. We aimed to investigate short-term efficacy, pharmacokinetic/pharma- codynamic (PK/PD) relations, and safety of ICL670, a novel, tridentate, orally active iron chelator.We enrolled 24 patients and divided them into three cohorts consisting of a minimum of seven individuals. Patients were admitted to a metabolic unit and consumed a diet with a defined content of iron. Two patients in each cohort were randomly allocated placebo. Five or more patients received one daily dose of ICL670 at 10, 20, or 40 mg x kg(-1) x day(-1), from day 1 to 12. Net iron excretion (NIE) was measured between days 1 and 12. Primary objectives included assessment of safety and tolerability (measured by adverse events and clinical laboratory monitoring), pharmacokinetics (measured as drug and drug-iron complex), and cumulative net iron excretion (measured by faecal and urine output minus food input). Analysis was for efficacy.ICL670 was absorbed promptly and was detectable in the blood for 24 h. Exposure (area under the curve of plasma concentration) to ICL670 at pharmacokinetic steady state was proportional to dose. All three doses resulted in positive NIE. The NIE achieved at 20mg x kg(-1) day(-1) would prevent net iron accumulation in most patients transfused with 12-15 mL packed red-blood-cells kg(-1) month(-1), equivalent to 0.3-0.5 mg iron kg(-1) x day(-1). A linear relation (PK/PD) was recorded between exposure to ICL670 and total iron excretion, by contrast with placebo (r2=0.54, p<0.0001). Skin rashes were noted in four patients treated at 20 and 40 mg x kg(-1) x day(-1), and one patient also developed grade 2 transaminitis.ICL670 given once daily at 20 mg/kg seems to be an effective orally active iron chelator and is reasonably well tolerated. Long-term studies are now necessary to establish the practical contribution of this drug." @default.
• W2005746290 created "2016-06-24" @default.
• W2005746290 creator A5010364362 @default.
• W2005746290 creator A5024304426 @default.
• W2005746290 creator A5029191905 @default.
• W2005746290 creator A5041652287 @default.
• W2005746290 creator A5043889585 @default.
• W2005746290 creator A5048556433 @default.
• W2005746290 creator A5061250423 @default.
• W2005746290 creator A5067753758 @default.
• W2005746290 creator A5072631536 @default.
• W2005746290 creator A5078761568 @default.
• W2005746290 creator A5081563686 @default.
• W2005746290 date "2003-05-01" @default.
• W2005746290 modified "2023-10-17" @default.
• W2005746290 title "Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial" @default.
• W2005746290 cites W1965206528 @default.
• W2005746290 cites W1983523884 @default.
• W2005746290 cites W1983683381 @default.
• W2005746290 cites W2001188398 @default.
• W2005746290 cites W2005969591 @default.
• W2005746290 cites W2023573435 @default.
• W2005746290 cites W2025254956 @default.
• W2005746290 cites W2031430208 @default.
• W2005746290 cites W2033066083 @default.
• W2005746290 cites W2049030903 @default.
• W2005746290 cites W2067150047 @default.
• W2005746290 cites W2069553612 @default.
• W2005746290 cites W2093823520 @default.
• W2005746290 cites W2097349200 @default.
• W2005746290 cites W2140055542 @default.
• W2005746290 cites W2284472461 @default.
• W2005746290 cites W2312723416 @default.
• W2005746290 cites W2317072972 @default.
• W2005746290 cites W2331162460 @default.
• W2005746290 cites W2334308892 @default.
• W2005746290 doi "https://doi.org/10.1016/s0140-6736(03)13309-0" @default.
• W2005746290 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12747879" @default.
• W2005746290 hasPublicationYear "2003" @default.
• W2005746290 type Work @default.
• W2005746290 sameAs 2005746290 @default.
• W2005746290 citedByCount "307" @default.
• W2005746290 countsByYear W20057462902012 @default.
• W2005746290 countsByYear W20057462902013 @default.
• W2005746290 countsByYear W20057462902014 @default.
• W2005746290 countsByYear W20057462902015 @default.
• W2005746290 countsByYear W20057462902016 @default.
• W2005746290 countsByYear W20057462902017 @default.
• W2005746290 countsByYear W20057462902018 @default.
• W2005746290 countsByYear W20057462902019 @default.
• W2005746290 countsByYear W20057462902020 @default.
• W2005746290 countsByYear W20057462902021 @default.
• W2005746290 countsByYear W20057462902022 @default.
• W2005746290 countsByYear W20057462902023 @default.
• W2005746290 crossrefType "journal-article" @default.
• W2005746290 hasAuthorship W2005746290A5010364362 @default.
• W2005746290 hasAuthorship W2005746290A5024304426 @default.
• W2005746290 hasAuthorship W2005746290A5029191905 @default.
• W2005746290 hasAuthorship W2005746290A5041652287 @default.
• W2005746290 hasAuthorship W2005746290A5043889585 @default.
• W2005746290 hasAuthorship W2005746290A5048556433 @default.
• W2005746290 hasAuthorship W2005746290A5061250423 @default.
• W2005746290 hasAuthorship W2005746290A5067753758 @default.
• W2005746290 hasAuthorship W2005746290A5072631536 @default.
• W2005746290 hasAuthorship W2005746290A5078761568 @default.
• W2005746290 hasAuthorship W2005746290A5081563686 @default.
• W2005746290 hasConcept C10146269 @default.
• W2005746290 hasConcept C112705442 @default.
• W2005746290 hasConcept C126322002 @default.
• W2005746290 hasConcept C142724271 @default.
• W2005746290 hasConcept C197934379 @default.
• W2005746290 hasConcept C204787440 @default.
• W2005746290 hasConcept C27081682 @default.
• W2005746290 hasConcept C2778375690 @default.
• W2005746290 hasConcept C2780026642 @default.
• W2005746290 hasConcept C71924100 @default.
• W2005746290 hasConcept C72563966 @default.
• W2005746290 hasConcept C90924648 @default.
• W2005746290 hasConceptScore W2005746290C10146269 @default.
• W2005746290 hasConceptScore W2005746290C112705442 @default.
• W2005746290 hasConceptScore W2005746290C126322002 @default.
• W2005746290 hasConceptScore W2005746290C142724271 @default.
• W2005746290 hasConceptScore W2005746290C197934379 @default.
• W2005746290 hasConceptScore W2005746290C204787440 @default.
• W2005746290 hasConceptScore W2005746290C27081682 @default.
• W2005746290 hasConceptScore W2005746290C2778375690 @default.
• W2005746290 hasConceptScore W2005746290C2780026642 @default.
• W2005746290 hasConceptScore W2005746290C71924100 @default.
• W2005746290 hasConceptScore W2005746290C72563966 @default.
• W2005746290 hasConceptScore W2005746290C90924648 @default.
• W2005746290 hasIssue "9369" @default.
• W2005746290 hasLocation W20057462901 @default.
• W2005746290 hasLocation W20057462902 @default.
• W2005746290 hasOpenAccess W2005746290 @default.
• W2005746290 hasPrimaryLocation W20057462901 @default.
• W2005746290 hasRelatedWork W1523134308 @default.
• W2005746290 hasRelatedWork W1830687917 @default.
• W2005746290 hasRelatedWork W1966047811 @default.

• next